RELATED STUDY
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
Key Findings: This study of adjuvant N-palmitoylethanolamide (PEA) for treating negaative symptoms in patients with schizophrenia found that PEA was safe and effective.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 50
Study Result: Positive
Study Location(s): Iran
Year of Pub: 2022
Cannabinoids Studied: Anandamide (AEA), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Ligands Studied: Dopamine, Glutamate
Dosage: PEA (600 mg twice a day)